Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + FOLFIRI +/- HAI in Metastatic Colorectal Cancer
NCT03069950Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of floxuridine in colorectal cancer (metastatic) (mCRC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Resection rate assessed using RECIST (version 1.1) at 3 months. Planned start Feb 2017; status: withdrawn.
02
Drugs
floxuridine
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03069950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069950.